Case Report: Zoledronic acid-induced hyperprogression in oncology: a case study of RET-driven neuroendocrine carcinoma treated with Selpercatinib - Top-Institutions - MDSpire

Case Report: Zoledronic acid-induced hyperprogression in oncology: a case study of RET-driven neuroendocrine carcinoma treated with Selpercatinib

  • By

  • Junqi Liu

  • FengJiao He

  • June 4, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology

  • #3

    Weill Cornell Medical Center
    Weill Cornell Medical Center

    New York, NY

    Key Differentiators

    • Oncology

  • #4

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Oncology

  • #5

    Jilin Provincial Cancer Hospital
    Jilin Provincial Cancer Hospital

    Jilin, China

    Key Differentiators

    • Oncology

Original Source(s)

Case Report: Zoledronic acid-induced hyperprogression in oncology: a case study of RET-driven neuroendocrine carcinoma treated with Selpercatinib

  • by Junqi Liu, FengJiao He

  • June 4, 2026

Related Content

Predicting survival in oral squamous cell carcinoma via integrated analysis of tumor budding and tertiary lymphoid structures

Emerging insights into the role of BDH1 in the pathogenesis of human cancer

Clonal Hematopoiesis does not influence manufacturing of Chimeric Antigen Receptor (CAR) T-Cells